First FDA-Approved Treatment for Alexander Disease

Zanvastro (zilganersen) is a glial fibrillary acidic protein (GFAP)–directed antisense oligonucleotide. Alexander disease is driven by pathogenic variants in GFAP: abnormal GFAP builds up in astrocytes and damages the nervous system over time. The disease affects fewer than 1 in a million people. Until this label, care was supportive — seizures, motor decline, raised intracranial pressure, and other complications managed without a disease-directed drug.

Zanvastro works by binding GFAP pre-mRNA so less GFAP protein is made. It is not a gene therapy, not a cure, and not an oral medicine. It is given into the spinal canal (intrathecal) after the vial is diluted with the accompanying aCSF diluent.

The FDA approved NDA 220210 on 3 September 2026. It is listed on FDA’s Novel Drug Approvals for 2026 table (row 37). The approval was granted to Ionis Pharmaceuticals, Inc. This is the first FDA-approved treatment for Alexander disease and the first therapy that directly targets the protein buildup that drives it.

Where this is taking place

Commercial labelled supply today: United States — FDA full approval (not accelerated on the press announcement; NDA 220210 approved for use as labelled). Administration is clinic-based: lumbar puncture by, or under the direction of, clinicians experienced in lumbar punctures. This is not a home injection.

Outside the United States: As of this draft, no Health Canada NOC, EC marketing authorisation, MHRA licence, PMDA/MHLW licence, TGA ARTG listing, Swissmedic authorisation, or NMPA decision has been confirmed from primary regulator pages for this article. Company disclosures describe an ex-US commercial partner and planned regulatory submissions in Europe and Japan expected in 2027. Expected filing ≠ approval.

Pivotal study — NCT04849741 (ION373 / zilganersen in Alexander disease) — Phase 1–3, multicentre, randomised, double-blind, controlled Main Study plus open-label infant substudy. Sponsor: Ionis Pharmaceuticals, Inc. CT.gov status at last update (21 August 2026): ACTIVE_NOT_RECRUITING. Primary completion 22 August 2025 (actual); study completion estimated July 2034 (long-term extension). This is not an enrolment door for newly labelled commercial use. Sites listed on CT.gov include United States (Stanford / Palo Alto; Children’s Healthcare of Atlanta; Massachusetts General Hospital, Boston; Children’s Hospital of Philadelphia), Canada (McGill University Health Centre, Montreal), Australia (Murdoch Children’s Research Institute, Parkville), Israel (Tel Aviv Sourasky), Italy (Milan; Rome), Japan (National Center of Neurology and Psychiatry, Tokyo), Netherlands (Amsterdam UMC), and United Kingdom (UCLH; Great Ormond Street). CT.gov does not name principal investigators for this record. A Canadian trial site is not a Canadian marketing authorisation.

Ultra-rare reality: the practical door in the US is a neurology / leukodystrophy centre that can schedule serial lumbar punctures, prepare the aCSF dilution correctly, and monitor for post–lumbar puncture syndrome and aseptic meningitis — not a general paediatrician writing a mail-order script.

Approval matrix

Access by country

• United States: Ask a neurologist experienced in leukodystrophy / Alexander disease (or a centre that already does therapeutic lumbar punctures) about FDA-labelled Zanvastro. Labelled 3 September 2026 for pediatric and adult patients with Alexander disease. Dose: 50 mg intrathecally every 3 months after dilution with the co-packaged aCSF diluent; bolus over 1 to 3 minutes. Age determines the injection volume after dilution (see dosing below) — the milligram dose stays 50 mg. Prior authorisation and specialty distribution still apply. No list price or copay dollars in this article. Ionis prescribing / IFU contact on label: https://www.ZANVASTRO.com or 1-833-644-6647. Report suspected adverse reactions to Ionis at that number or FDA MedWatch 1-800-FDA-1088. This is US commercial labelled supply, not Special Access and not a DIY import.

• Canada: Authorisation not confirmed. McGill University Health Centre appears on the NCT04849741 site list — that is a trial location, not a Notice of Compliance. Do not assume SAP, named-patient, or cross-border mail-order is available or appropriate. Ask the AxD / leukodystrophy clinic what legal paths exist in Canada when a Canadian label does not yet exist.

• European Union / United Kingdom: Authorisation not confirmed. Company materials describe Europe submissions expected in 2027. That is a planned filing, not a marketing authorisation. UK trial sites (UCLH; Great Ormond Street) are not an MHRA licence.

• Japan: Authorisation not confirmed. Company materials describe Japan submissions expected in 2027. The National Center of Neurology and Psychiatry (Tokyo) trial site is not a PMDA/MHLW licence.

• Australia / Israel / Italy / Netherlands / other countries with trial sites: Trial participation or completed enrolment is not a commercial label. Regulator authorisation not confirmed in this draft.

• If your regulator has not authorised it: do not import on your own. Travelling to the United States for labelled IT dosing is a plan made with both specialists, not a suitcase protocol. Intrathecal medicine is not something you carry through customs and self-inject.

Who is eligible (from the US label)

This is an Alexander disease conversation — clinical phenotype, brain MRI pattern, and a pathogenic GFAP variant were how the pivotal study defined the disease. The US indication is broad: pediatric and adult patients with Alexander disease. It does not restrict to one age band on the indication line.

United States (Prescribing Information, revised 09/2026):

• Indication: Treatment of Alexander disease in pediatric and adult patients.
• Dose: 50 mg intrathecally every 3 months, after dilution with the accompanying aCSF diluent.
• Given by lumbar puncture by, or under the direction of, healthcare professionals experienced in performing lumbar punctures.
• Final dose volume after dilution depends on age (label Table 1 / Table 2):
  • Less than 2 years: 10 mL
  • 2 to 7 years (inclusive): 15 mL
  • 8 years and older: 20 mL
• Before injection, remove a volume of the patient’s CSF approximately equal to the intended dose volume, as appropriate for age.
• Missed dose: give as soon as possible; then resume the every-3-months schedule from the date of the most recent dose.
• Contraindications: None.
• Pediatrics: Safety and effectiveness established for pediatric patients; support for under 2 years includes the Main Study in patients ≥2 years, pharmacokinetic modelling (CSF exposure after 50 mg expected similar to older children), and safety data in 4 patients under 2 years in the open-label substudy.
• Geriatrics: Not studied in patients ≥65 years; no data to say whether they respond differently.
• Pregnancy / lactation: No adequate human data; animal data exist — clinic reads the label with you.
• Not a substitute for seizure care, feeding support, physiotherapy, or other supportive AxD care.

Not labelled / not inventable from a press release:

• EU, UK, Canadian, Japanese, Australian, Swiss, or Chinese marketing authorisations (not confirmed here).
• Oral, subcutaneous, or IV home administration.
• A dose other than 50 mg IT every 3 months as the recommended regimen (the pivotal study also tested 25 mg; that is not the labelled dose).

What the pivotal study showed (US label / FDA press)

Efficacy below is from the US Prescribing Information and the FDA 3 September 2026 press announcement — not from an EU label (none confirmed).

Study 1 — NCT04849741 (USPI Section 14):

• Multicentre study in pediatric and adult patients with Alexander disease.
• Main Study: double-blind, randomised, controlled; 49 patients aged 2 to 65 years.
• Open-label substudy: 4 patients less than 2 years of age.
• Diagnosis required: clinical phenotype, brain MRI, and a pathogenic GFAP variant.
• Double-blind period: ascending-dose cohorts 25 mg (n=8 randomised to drug in that cohort’s 2:1 split) or 50 mg (n=24), each cohort randomised 2:1 to Zanvastro every 12 weeks or control (n=17 control overall). Double-blind ended at Week 61.
• Stratification: Stratum 1 — patients ≥5 years who (if ≥18) had motor symptom onset within 5 years and had an abnormality in gross motor skills; Stratum 2 — all other enrolled patients. Primary endpoint analysed in Stratum 1; secondary endpoints in the full Main Study population.
• Baseline (Main Study n=49): median age 11 years; mean 10-metre walk-test gait speed 1.2 m/sec; 65% female; 86% White.

Primary efficacy (Stratum 1, labelled 50 mg cohort):

• Mean percent change in gait speed (10-Meter Walk Test) from baseline to Week 61: −2.1% with Zanvastro 50 mg vs −35.4% with control.
• Adjusted least-squares mean difference: 33.3% (95% CI 1.44, 65.25), p = 0.041.
• FDA press framing: in patients 5 years and older with measurable walking difficulty at baseline, treated patients showed significantly better walking speed at 61 weeks than those who received no treatment.

Ages 2–4 years (GMFM-88 alternate endpoint):

• Standing (Dimension D) plus walking/running/jumping (Dimension E): treated children (n=4) improved; control (n=3) declined.
• Least-squares mean difference: 22.9 (SE 5.2).
• FDA press: walking speed is not a reliable measure in this age band, so a broader motor-skills assessment was used.

Under 2 years:

• Direct efficacy with concurrent control was limited by rarity.
• Extension of the indication relied on pharmacokinetic modelling (expected similar drug levels at 50 mg), safety in the 4 infants treated, and safety in older pediatric patients.

Pharmacodynamics (label):

• At Week 61 (after 5 doses), geometric mean ratio to baseline in plasma GFAP was 33.6% lower on Zanvastro than on control (indirect target-engagement marker).

Trial status honesty: NCT04849741 remains ACTIVE_NOT_RECRUITING for long-term follow-up (estimated completion 2034). It is not a path to start labelled drug outside commercial US distribution.

Dose and how it is given (on-label)

Safety (what the label and FDA press put first)

Warning — aseptic meningitis: Zanvastro can cause aseptic (chemical / drug-induced) meningitis. Contact the treating clinician if meningitis-like symptoms develop (for example severe headache, stiff neck, fever, photophobia, confusion — the clinic will define the workup). In Study 1, one patient had a serious aseptic meningitis event in the double-blind period that recurred in open-label extension, required dose interruption, and later used IV dexamethasone pretreatment; CSF WBC and protein still rose with continued exposure though the patient remained asymptomatic and stayed on treatment. Nonserious CSF white-cell increases were also reported.

Most common adverse reactions (double-blind; incidence >25% on Zanvastro 50 mg and greater than control): vomiting, back pain, cough, headache, post–lumbar puncture syndrome.

Also more common on drug than control (≥10% and ≥10% above control) per USPI Table 3: arthralgia, oropharyngeal pain, dysphagia (rates on 50 mg: vomiting 50%, back pain 50%, cough 38%, headache 29%, post-LP syndrome 29%, arthralgia 25%, oropharyngeal pain 21%, dysphagia 17%).

CSF pleocytosis: increased CSF WBC after early doses in 7/24 (29%) on 50 mg vs 3/17 (18%) control in the double-blind Main Study, plus additional open-label cases.

Immunogenicity: 9/32 (28.1%) treated patients developed treatment-emergent anti-drug antibodies in the evaluated set; no clear overall effect on safety/efficacy in the limited data; one patient with high ADA titres had CSF findings with possible aseptic meningitis signs.

Contraindications: none listed.

Postmarketing requirements (approval letter): carcinogenicity studies (mouse and rat), rabbit embryo-fetal development, pre-/postnatal development, and a leachables CNS toxicity study — these are sponsor obligations, not clinic visits you book from this article.

How to talk to a doctor

Bring the NCT number, the NDA number, and the US Prescribing Information if you are in a US clinic. Outside the US, bring honesty that a local label may not exist yet.

1. "I / my child has Alexander disease with a pathogenic GFAP variant and MRI/clinical phenotype. Is Zanvastro the labelled next step in this country?"
2. "In the United States, the label is 50 mg intrathecal every 3 months after aCSF dilution. Who at this centre performs therapeutic lumbar punctures for antisense drugs?"
3. "What is the plan for post–lumbar puncture syndrome (headache, back pain) and for watching aseptic meningitis symptoms after each dose?"
4. "Confirm the age-based injection volume after dilution — 10 / 15 / 20 mL — while the dose stays 50 mg."
5. "Is prior authorisation started? Who coordinates specialty pharmacy and the NDC 71860-304-01 carton (drug + diluent)?"
6. "We will not try to import EU/Japan stock or invent a foreign compassionate ID — those licences are not confirmed."
7. "If we are outside the US, what legal options exist while company filings for Europe/Japan are described as 2027 expectations — trial extension, local special-access rules, or referral — without DIY import?"
8. "Supportive AxD care (seizures, tone, feeding, school/rehab) continues. Zanvastro does not replace that."

Research and regulatory team (from sources only — no invented contacts)

• Ionis Pharmaceuticals, Inc., Carlsbad, CA — NDA 220210 applicant and approval holder; NCT04849741 lead sponsor; US distributor named on the Prescribing Information / Instructions for Use.
• Christine Pai, PhD, Associate Director, Regulatory Affairs, Ionis — addressee on the FDA approval letter.
• Teresa Buracchio, MD, Director, Office of Neuroscience, CDER — signed the 3 September 2026 approval letter.
• Brenda Reggettz, PharmD, Regulatory Health Project Manager — named contact on the approval letter for applicant questions to FDA.
• Emily Freilich, MD, Director, Division of Neurology I, CDER — quoted in the FDA press announcement on the approval.
• NCT04849741 site facilities (CT.gov; no overall officials or central contacts listed on the record retrieved): Lucile Packard Children’s Hospital Stanford (Palo Alto, US); Children’s Hospital of Atlanta (US); Massachusetts General Hospital (Boston, US); Children’s Hospital of Philadelphia (US); Murdoch Children’s Research Institute (Parkville, Australia); McGill University Health Centre (Montreal, Canada); Dana-Dwek Children’s Hospital / Tel Aviv Sourasky (Israel); Ospedale dei Bambini Vittore Buzzi (Milan, Italy); Ospedale Pediatrico Bambino Gesù (Rome, Italy); National Center of Neurology and Psychiatry (Tokyo, Japan); Amsterdam UMC (Netherlands); University College London Hospitals and Great Ormond Street Hospital (London, UK).
• Principal-investigator names, patient-support emails, or ex-US medical-information lines are listed only when they appear on the US label or the primary pages below.

Bottom line

Zanvastro (zilganersen) is the first FDA-approved treatment for Alexander disease, labelled 3 September 2026 (NDA 220210) for pediatric and adult patients. It is a GFAP-directed antisense given as 50 mg into the spinal canal every three months after aCSF dilution, by clinicians who do lumbar punctures. The pivotal study (NCT04849741) showed better gait-speed change at Week 61 in older patients and improved gross-motor scores in ages 2–4 versus control. Watch for aseptic meningitis and post–LP symptoms. US labelled; other regulators not confirmed. Company plans for Europe and Japan filings in 2027 are not approvals. Ultra-rare: the door is a neurology centre that can deliver serial IT dosing safely — not a suitcase, not a home pen.

---

Primary sources

1. FDA press announcement — FDA Approves First Drug to Treat Alexander Disease, Immediate Release 3 September 2026 — https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-alexander-disease
2. FDA approval letter, NDA 220210, Zanvastro (zilganersen) injection, signed 3 September 2026 (Teresa Buracchio, MD) — https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220210Orig1s000ltr.pdf
3. Zanvastro (zilganersen) Prescribing Information / Instructions for Use, revised 09/2026 (Ionis) — https://ionis.com/medicines/ZANVASTRO/ZANVASTRO-FPI.pdf
4. FDA Novel Drug Approvals for 2026 — Zanvastro / zilganersen, approval date 9/3/2026, row 37 — https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
5. ClinicalTrials.gov NCT04849741 — A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD) — https://clinicaltrials.gov/study/NCT04849741